ABSTRACT Purpose: This work targets assessing the estimation of intracameral bevacizumab infusion in treatment of rubeosis iridis in neovascular glaucoma. Patients and strategies: A planned report was done on 30 eyes of 30 patients with rubeosis iridis. Intracameral infusion of bevacizumab was infused for all patients. Iris flourescein angiography and specular microscopy were performed to all patients preoperatively and postoperatively. Patients were followed up at five days, one month, a quarter of a year, and a half year spans following the system. Results: Iris fluorescein angiography demonstrated neovascularization relapse just in the early development. Notwithstanding, specular microscopy indicated practically stable endothelial trustworthiness aside from a couple of cases. Conclusion: The utilization of intracameral bevacizumab for rubeosis iridis still needs more preliminaries to build up long haul security and viability in retinal ischemia and neovascular glaucoma.